

# Benjamin L Maughan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2399597/publications.pdf>

Version: 2024-02-01

31  
papers

622  
citations

623734

14  
h-index

610901

24  
g-index

32  
all docs

32  
docs citations

32  
times ranked

953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	1.6	69
2	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	1.6	69
3	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	1.6	57
4	Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 6.	3.0	47
5	Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. <i>Oncotarget</i> , 2017, 8, 33614-33620.	1.8	45
6	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	3.7	33
7	Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100116.	1.7	29
8	A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 121-e213.	3.7	28
9	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	1.9	27
10	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , The, 2022, 23, 899-909.	10.7	26
11	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
12	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. <i>Current Treatment Options in Oncology</i> , 2019, 20, 14.	3.0	16
13	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. <i>Research and Reports in Urology</i> , 2018, Volume 10, 205-217.	1.0	15
14	&lt;p&gt;Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749.	1.9	15
15	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2104-2110.	7.0	15
16	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. <i>Oncologist</i> , 2021, 26, 1006-e2129.	3.7	13
17	Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. <i>Oncologist</i> , 2018, 23, 1413-e151.	3.7	11
18	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100120.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Molecular Cancer Therapeutics</i> , 2019, 18, 726-729.	4.1	9
20	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4807-4813.	7.0	9
21	Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760.	3.7	9
22	Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210415.	2.5	8
23	What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. <i>Prostate</i> , 2020, 80, 441-450.	2.3	8
24	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e169-e172.	1.9	7
25	Pathogenic Germline DNA Repair Gene and <i>HOXB13</i> Mutations in Men With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 139-151.	3.0	7
26	Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e573-e584.	1.9	6
27	Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. <i>Drugs and Aging</i> , 2019, 36, 395-401.	2.7	5
28	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632.	1.8	5
29	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, E1-E6.	1.0	3
30	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726.	1.0	2
31	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 308-308.	1.6	0